TLX vs ABVX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TLX Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Telix Pharmaceuticals Limited American Depositary Shares (TLX) driven by superior Valuation, Growth & Margin, Momentum & Technical while ABVX counters with relative strength in Options & Structure. Fundamentally, TLX trades at N/M Forward P/E with 6.2% operating margin (+22.3% YoY revenue) versus ABVX at N/M Forward P/E and -6270.4% operating margin (-6.8% YoY). In options structure, TLX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABVX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TLX | ABVX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2B | $7.9B | Larger Scale | ABVX |
| Trailing P/E Ratio Valuation | 93.6x | N/M | Lower Multiple | TLX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +22.3% | -6.8% | Higher Growth | TLX |
| Operating Margin (TTM) Profitability | 6.2% | -6270.4% | Higher Margin | TLX |
| Net Profit Margin Profitability | 3.8% | 0.0% | Higher Margin | TLX |
| Return on Equity (ROE) Capital Efficiency | 7.4% | -252.3% | Higher ROE | TLX |
| 52-Week Range Position Momentum | 40% ($6โ$13) | 18% ($70โ$149) | Stronger Trend | TLX |
| Beta / 30D Volatility Risk Regime | 0.84ฮฒ ยท 62% Vol | 1.38ฮฒ ยท 47% Vol | Lower Realized Risk | ABVX |
| Unified Institutional Score Composite Signal | 46.4 / 100 (HOLD) | 55.6 / 100 (HOLD) | Higher Composite | ABVX |